Compare Quest Diagnostics Inc (DGX) vs SPDR Gold Trust (GLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs SPDR Gold Trust — how do they compare? Quest Diagnostics Inc trades at $231.55 (market cap $25.48B), while SPDR Gold Trust trades at $384.77 (market cap $139.66B). The key difference: SPDR Gold Trust is far larger — about 5.5× Quest Diagnostics Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while SPDR Gold Trust pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and SPDR Gold Trust for 74 Days on average.
| DGX | GLD | |
|---|---|---|
Market Cap | $25.48B | $139.66B |
Volume | 941,866 | 9,544,773 |
Sector | Health | — |
52-Week High | $247.45 | $495.90 |
52-Week Low | $173.49 | $362.32 |
Typical Hold Time | 56 Days | 74 Days |
Enterprise Value | $31.23B | — |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
GLD, the SPDR Gold Trust ETF, trades at $384.77 with a 2.37% daily gain amid bearish technical signals. The stock faces pressure from rising Treasury yields and Federal Reserve rate expectations, though recent weak employment data provided temporary support. Technical indicators show strong bearish momentum with moving averages signaling sell pressure, while oscillators remain neutral. The ETF is testing key resistance levels with support at $373-$377 and resistance at $380-$384.
The outlook remains cautious as gold faces headwinds from monetary policy tightening and dollar strength. While serving as a traditional inflation hedge, GLD's near-term performance depends on interest rate trajectory and safe-haven demand. Risks include further Fed hawkishness and declining institutional interest, though long-term diversification benefits persist for portfolio allocation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About SPDR Gold Trust
GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →
